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Introduction
Esophageal squamous cell cancer (ESCC) is associated with a poor prognosis and high recurrence rate despite improvement in early diagnosis and multimodal treatments including operation, chemotherapy and irradiation. Searching for molecular targets of ESCC is critical to improve the effect of treatment [1] [2] [3] . According to recent reports, epidermal growth factor receptor (EGFR) is highly expressed in invasive ESCC, and patients with EGFR-overexpressing esophageal cancers have a poorer prognosis and more lymph node metastases than those with EGFR-negative tumors [4] [5] [6] .
EGFR belongs to the type I receptor tyrosine kinase family, which includes ErbB2/ HER2, ErbB3, and ErbB4 and is implicated in the cell proliferation, angiogenesis, invasion and survival of neoplastic cells [7] . The regulation of these family members is complex, as the receptors can be transactivated by homodimeric interaction between two family members and thus uses multiple pathways to execute their biological functions [8] . The presence of deregulated EGFR-tyrosine kinase (TK) has been confirmed in many types of solid tumors, such as head and neck cancers, colon cancers, non-small cell lung cancers (NSCLC), and breast cancers. Considered together, growth factors and their receptors, therefore, play an essential role in cancer pathogenesis and progression, and they are considered important targets for anticancer therapy [9-11].
ZD1839 (Iressa ® , AstraZeneca) is an orally administered, small-molecule EGFR-TK inhibitor (EGFR-TKI) that blocks signal transduction pathways implicated in proliferation and survival of cancer cells, as well as other host-dependent processes that promote cancer growth. ZD1839 has broad antitumor effect against various types of solid tumors, including NSCLC, colorectal, breast, and head and neck cancers [12] [13] [14] , and has been clinically approved for the treatment of advanced NSCLC.
Moreover, various additive/cooperative effects have been reported for many kinds of solid tumors both in vitro and in vivo when ZD1839 is combined with other chemotherapeutic agents or radiotherapy [15] [16] [17] . Based on the above studies, ZD1839 is anticipated to exert antitumor effects on ESCC. When clinically assessed in a Phase II trial as second-line treatment for advanced esophageal cancer, in which 9 out of 36 enrolled patients had ESCC, a total of 3 patients (10%) had partial responses and seven patients (23%) had stable disease [18] . The results were less than ideal and multidisciplinary strategies are required.
Tumor necrosis factor-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF family and a potent proapoptotic ligand in broad variety of tumor The results showed that inhibition of EGFR mediated Akt phosphorylation by ZD1839 led to Bcl-xL inactivation and caspase-9 activation in TE8 cells, thereby promoting apoptosis of cells through a mitochondrial-dependent apoptotic pathway.
The findings suggest that treatment with ZD1839 alone or in combination with TRAIL is a promising strategy for ESCC.
Materials and methods

Cells and culture conditions
The human ESCC cell lines (TE1, TE6, TE8 and TTn) were propagated in monolayer cultures in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 100 units/ml penicillin, and 100 mg/ml streptomycin. ESCC cells were maintained under 5% CO 2 at 37 o C. Cells were treated with the indicated concentration of ZD1839
(10-100 µM) or TRAIL (0.1-500 ng/ml) for the indicated interval. TE8 cells were treated with 1 µM ZD1839 combined with or without 100 ng/ml TRAIL for various time intervals (1, 3, 6 , 12, and 24 h). Cells were harvested, and prepared for each experiment as described below.
Reagents
ZD1839 (Gefitinib, 'Iressa') was a kind gift from AstraZeneca (Macclesfield, United Kingdom), dissolved in dimethyl sulfoxide (DMSO) at 10 mM and stored at -20 o C as a master stock solution. The drugs were diluted in fresh media before each experiment. EGF was purchased from Sigma Chemical Co. (St. Louis, MO), dissolved in DMSO at 100 µg/ml, and stored at -20 o C. Human recombinant TRAIL was purchased from Calbiochem (San Diego, CA), dissolved in phosphate-buffered saline (PBS) at 100 µg/ml, and stored at -80 o C. In all experiments, the final DMSO concentration was < 0.1%.
Cell proliferation assay
The cell growth inhibitory effects of ZD1839 or/and TRAIL on ESCC cells were determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as described previously [24] . Cell viability was calculated: 100 x A treatment /A control (%). The IC 50 value was the concentration of ZD1839 that resulted in 50% inhibition in absorbance according to the Curve Fit 1.3 program.
Flow cytometry analysis
Cells treated with various concentrations of ZD1839 were harvested in 0.125% trypsin, washed twice in PBS with 2% FCS. After centrifugation, 1 x 10 6 cells were resuspended in PBS containing 0.1% Triton X-100 and 10 µg/ml RNase A (Sigma)
for 5 min at room temperature. The samples were then stained with 10 µg/ml PI All experiments were repeated at least twice.
Antibodies and Western blot analysis
The following antibodies were used: anti-EGFR, cyclinD1 and Bcl-xL (Santa 
Statistical analysis
Data are expressed as mean ± SD. Differences in the cell growth inhibition effect for the treatment groups were compared using the Student's t-test. Statistical significance was defined as p < 0.05.
Results
Overexpression of EGFR and effects of ZD1839 on cell growth in human ESCC cells
ESCC cell lines expressed different levels of EGFR, HER2, phosphorylation of EGFR, and phosphorylation of tyrosine determined by Western blot analysis (Fig. 1A) .
EGF, the specific ligand of EGFR, increased the level of phosphorylation of EGFR and tyrosine, and was used as positive control in further experiments. TE8 cells were autophosphorylated to EGFR without EGF.
We next determined the effects of ZD1839, an EGFR-TKI, on the cell proliferation using the MTT assay. Cells were treated with various concentrations 
ZD1839 treatment induces G 1 phase arrest and up-regulation of p27
To elucidate the mechanisms of ZD1839 induced growth inhibition in ZD1839-sensitive TE1 cells, we first tested the effects of ZD1839 on the phosphorylation of EGFR. ZD1839 treatment for 24 h down-regulated phosphorylation of EGFR in TE1 cells, while basal EGFR protein level did not change over the same period ( Fig. 2A ). These data confirmed that ZD1839 effectively inhibited TK-related phosphorylation of EGFR. Moreover, treatment with ZD1839 resulted in inhibition of TE1 cell growth but not control cells, as confirmed by morphological examination (Fig. 2B ). To determine the effects of ZD1839 on the cell-cycle profile, TE1 cells were treated with 0-10 µM ZD1839 for 24 h and then the cell cycle distribution was analyzed by FACS. The cell cycle was arrested at G 1 phase in a ZD1839 dose-dependent manner, but sub-G 1 fraction indicative of apoptosis was very small (Fig. 2C ). Western blot analysis performed to evaluate the molecules related to the cell cycle regulation revealed that ZD1839 treatment of TE1 cells led to a slight increase in p21 protein level, and marked increase in p27 protein level in dose-and time-dependent manners, but had no effect on cyclin D1 and cdk4 protein levels ( Fig. 2D , E). These results suggest that ZD1839 treatment induced cell cycle arrest at G 1 phase via induction of p21 and p27 rather than apoptosis.
ZD1839 inhibits phosphorylation of EGFR and PI3k-Akt signaling pathway
ESCC cells expressed variable levels of the Akt and phosphorylated Akt, and EGF activated phosphorylation of Akt ( 
ZD1839-augmented TRAIL-induced apoptosis of TE8 cells involves activation of caspases and inactivation of Bcl-xL
Recently, one report demonstrated that various ESCC cell lines including TE8 cells were resistant to TRAIL [23] . Other studies showed that activation of the PI3k-Akt pathway rendered several types of cancer cells resistant to TRAIL-induced apoptosis [20, 21] . In the next step, we investigated whether ZD1839 could alter the TRAIL sensitivity of TE8 cells via Akt inactivation. In fact, TE8 cells overexpressing phosphorylated EGFR and Akt, and treatment with 500 ng/ml TRAIL did not significantly inhibit cell growth, suggesting that TE8 cells are resistant to TRAIL.
Moreover, TTn cells were also insensitive to 500 ng/ml TRAIL, and more resistant to TRAIL treatement than TE8 cells (Fig. 4A) . We further examined the effects of TRAIL on the growth of TE8 and TTn cells in vitro in the presence or absence of ZD1839. As shown in Fig. 4B , a synergistic increase in the growth inhibition rate was observed in TE8 cells treated with 100 ng/ml of TRAIL combined with 1 µM of ZD1839 for 24 h. TRAIL alone inhibited cell growth in approximately 17.5% of the cells, while treatment with ZD1839 and TRAIL further inhibited cell growth in 46.1% of the cells. ZD1839 alone had little effect on tumor cell viability (11%). We also found that treatment of TTn cells with 2 µM ZD1839 and 500 ng/ml TRAIL resulted in a marked inhibition of cell growth compared with TRAIL alone or ZD1839 alone;
the magnitude of the synergism in TTn cells, however, was less dramatic than that in TE8 cells, presumably due to the increased resistance in TTn cells. Microscopic examination showed numerous dead TE8 cells treated for 24 h with TRAIL plus ZD1839, indicating apoptosis of these cells (Fig. 4C ). Interestingly, ZD1839 or TRAIL alone had little effect on caspase-3 activity, but the combination with ZD1839
and TRAIL resulted in a marked increase of caspase-3 activity 3 h after treatment (Fig.   4D ). In addition, the result of Western blotting showed no effect for ZD1839 or little effect for TRAIL on the processing of caspase-3 or PARP. In contrast, the combination of ZD1839 and TRAIL resulted in cleavage of both of caspase-3 and PARP (Fig. 5A ). Taken together, these results indicate that ZD1839 augmentes TRAIL-induced apoptosis of TRAIL-resistant TE8 cells.
We further examined the effects of ZD1839 and TRAIL on changes of Bcl-xL, Bcl-xS and caspase-9 protein by western blotting. ZD1839 induced a slight induction of Bcl-xS protein. Moreover, ZD1839 plus TRAIL downregulate Bcl-xL, and activated caspase-9 (Fig. 5B) . These findings suggest that the augmentation of TRAIL-induced apoptosis by ZD1839 is mediated by an increase in active caspase-9, which is considered to be mediated by down-regulation of Bcl-xL. 
